Who owns Viridian Therapeutics, Inc.\DE?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of VRDN from SEC Form 13F filings across 214 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 214 institutions disclosed 136.0M shares of Viridian Therapeutics, Inc.\DE worth $2.50B — about 126.1% of shares outstanding; the largest disclosed holder is FMR LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
214
13F holders
$2.50B
value, 2026 filers
126.1%
of shares outstanding (136.0M sh)
46
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of VRDN's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | 16.6M | $305.0M | 0.0% | 15.4% | +8.0% |
| 2 | BlackRock, Inc. | 8.6M | $157.1M | 0.0% | 7.9% | +9.2% |
| 3 | Bellevue Group AG | 6.7M | $123.7M | 2.6% | 6.2% | +0.1% |
| 4 | Paradigm Biocapital Advisors LP | 6.7M | $123.5M | 2.3% | 6.2% | +113.5% |
| 5 | Kynam Capital Management, LP | 6.5M | $118.6M | 6.6% | 6% | +175.6% |
| 6 | STATE STREET CORP | 6.1M | $112.5M | 0.0% | 5.7% | +31.1% |
| 7 | PRICE T ROWE ASSOCIATES INC /MD/ | 5.7M | $105.6M | 0.0% | 5.3% | +79.3% |
| 8 | Fairmount Funds Management LLC | 5.1M | $93.5M | 6.2% | 4.7% | +30.1% |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | 4.6M | $84.1M | 0.0% | 4.2% | +9.8% |
| 10 | Deep Track Capital, LP | 3.6M | $66.0M | 1.0% | 3.3% | +157.7% |
| 11 | Venrock Adviser, LLC | 3.3M | $59.8M | 1.8% | 3% | -16.1% |
| 12 | WELLINGTON MANAGEMENT GROUP LLP | 3.1M | $57.5M | 0.0% | 2.9% | +1.6% |
| 13 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2.8M | $50.6M | 0.0% | 2.6% | +67.7% |
| 14 | GEODE CAPITAL MANAGEMENT, LLC | 2.5M | $46.0M | 0.0% | 2.3% | +7.2% |
| 15 | Avoro Capital Advisors LLC | 2.5M | $45.9M | 0.4% | 2.3% | +66.7% |
| 16 | BAKER BROS. ADVISORS LP | 2.4M | $43.8M | 0.2% | 2.2% | +20.9% |
| 17 | Point72 Asset Management, L.P. | 2.3M | $43.0M | 0.0% | 2.2% | +625.8% |
| 18 | Caligan Partners LPNEW | 2.2M | $40.3M | 1.9% | 2% | new |
| 19 | NOVO HOLDINGS A/S | 2.1M | $39.2M | 2.3% | 2% | +6.8% |
| 20 | TANG CAPITAL MANAGEMENT LLC | 1.8M | $32.9M | 1.5% | 1.7% | 0.0% |
| 21 | Fisher Asset Management, LLC | 1.8M | $32.2M | 0.0% | 1.6% | -1.0% |
| 22 | Candriam S.C.A. | 1.7M | $31.3M | 0.1% | 1.6% | +139.9% |
| 23 | GOLDMAN SACHS GROUP INC | 1.7M | $31.1M | 0.0% | 1.6% | +6.2% |
| 24 | First Turn Management, LLC | 1.7M | $30.7M | 3.3% | 1.5% | +83.2% |
| 25 | DIMENSIONAL FUND ADVISORS LP | 1.6M | $29.6M | 0.0% | 1.5% | +204.2% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.